<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The BCL2 (B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> -2) and C-MYC oncogenes become activated by chromosomal translocations involving the immunoglobulin heavy chain locus in human follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>Though much is known about the biological actions of C-MYC, little information is available concerning the functions of BCL2, particularly in human B cells </plain></SENT>
<SENT sid="2" pm="."><plain>Using a gene transfer approach we contrasted the effects of deregulated BCL2 and C-MYC expression in a human EBV-immortalized B cell line GM607B </plain></SENT>
<SENT sid="3" pm="."><plain>Both BCL2 and C-MYC enhanced the ability of GM607B cells to grow in reduced serum and in limiting dilution cultures </plain></SENT>
<SENT sid="4" pm="."><plain>These findings provide direct evidence that BCL2 can alter the growth characteristics of human B lymphocytes, thus strengthening arguments for its role in the pathogenesis of human <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>